Publications

Oncogene

A genome-wide CRISPR screen in human prostate cancer cells reveals drivers of macrophage-mediated cell killing and positions AR as a tumor-intrinsic immunomodulator.

01-09-2026

ACS chemical biology

Molecular Glue and Phosphorylation-Dependent 14-3-3 Recruitment to p53 with an Engineered Interaction Cassette.

21-08-2026

The FEBS journal

Inhibition of mitochondrial protein translation sensitizes tumor cells to death receptor 5 agonistic antibody.

29-07-2026

Blood

DOT1L Shapes ncPRC1-Target Gene Repression to Maintain Germinal Center B Cell Identity of Diffuse Large B cell Lymphoma.

29-05-2026

Nature protocols

Inducible CRISPR-Cas9 screening platform to interrogate non-proliferative cellular states.

01-05-2026

Journal of experimental & clinical cancer research : CR

CRISPR knockout screens reveal JUN as the master mediator of resistance to MAPK inhibition in KRAS-mutant pancreatic cancer.

22-01-2026

Neoplasia (New York, N.Y.)

Cholesterol biosynthesis as a drug-induced vulnerability in diffuse large B cell lymphoma insensitive to EZH2 inhibition.

01-12-2025

NAR cancer

Exploiting nanopore sequencing advances for tRNA sequencing of human cancer models.

01-12-2025

Proceedings of the National Academy of Sciences of the United States of America

CRISPR screens identify the ATPase VCP as a druggable therapeutic vulnerability in cholangiocarcinoma.

30-09-2025

Cell reports. Medicine

Epigenetic profiling identifies markers of endocrine resistance and therapeutic options for metastatic castration-resistant prostate cancer.

15-07-2025

bioRxiv : the preprint server for biology

A functionally validated TCR-pMHC database for TCR specificity model development.

12-05-2025

Genome biology

Molecular dependencies and genomic consequences of a global DNA damage tolerance defect.

31-12-2024

Proceedings of the National Academy of Sciences of the United States of America

An antibiotic that mediates immune destruction of senescent cancer cells.

24-12-2024

Cell

P-stalk ribosomes act as master regulators of cytokine-mediated processes.

27-11-2024

Nucleic acids research

ADARp150 counteracts whole genome duplication.

23-09-2024

Nucleic acids research

Chromatin context-dependent effects of epigenetic drugs on CRISPR-Cas9 editing.

27-08-2024

Cancer discovery

Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy.

01-07-2024

Nature communications

Widespread chromatin context-dependencies of DNA double-strand break repair proteins.

22-06-2024

Cell reports. Medicine

Targeting of vulnerabilities of drug-tolerant persisters identified through functional genetics delays tumor relapse.

19-03-2024

The EMBO journal

PARG-deficient tumor cells have an increased dependence on EXO1/FEN1-mediated DNA repair.

01-03-2024

EMBO molecular medicine

Luminal breast cancer identity is determined by loss of glucocorticoid receptor activity.

07-12-2023

Molecular cell

Locus-specific proteome decoding reveals Fpt1 as a chromatin-associated negative regulator of RNA polymerase III assembly.

07-12-2023

Nucleic acids research

PAXIP1 and STAG2 converge to maintain 3D genome architecture and facilitate promoter/enhancer contacts to enable stress hormone-dependent transcription.

13-10-2023

Molecular oncology

Rational combination of SHP2 and mTOR inhibition for the treatment of hepatocellular carcinoma.

01-06-2023

Cell reports

Multi-omics analysis reveals distinct non-reversion mechanisms of PARPi resistance in BRCA1- versus BRCA2-deficient mammary tumors.

30-05-2023

Breast cancer research : BCR

Systematic screening identifies ABCG2 as critical factor underlying synergy of kinase inhibitors with transcriptional CDK inhibitors.

05-05-2023

Cancer immunology research

Inhibitor of Apoptosis Proteins Antagonist Induces T-cell Proliferation after Cross-Presentation by Dendritic Cells.

03-04-2023

Journal of experimental & clinical cancer research : CR

Subtype-specific kinase dependency regulates growth and metastasis of poor-prognosis mesenchymal colorectal cancer.

03-03-2023

Haematologica

Inhibition of casein kinase 2 sensitizes mantle cell lymphoma to venetoclax through MCL-1 downregulation.

01-03-2023

Cell reports. Medicine

Genetic screens reveal new targetable vulnerabilities in BAP1-deficient mesothelioma.

21-02-2023

Proceedings of the National Academy of Sciences of the United States of America

Mammalian life depends on two distinct pathways of DNA damage tolerance.

24-01-2023

EBioMedicine

Sustained activation of EGFR-ERK1/2 signaling limits the response to tigecycline-induced mitochondrial respiratory deficiency in liver cancer.

01-01-2023

Molecular cancer therapeutics

NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition.

02-12-2022

Bio-protocol

An Unbiased CRISPR-Cas9 Screening Method for the Identification of Positive and Negative Regulatory Proteins of Cell Adhesion.

05-11-2022

Nature cancer

cFLIP suppression and DR5 activation sensitize senescent cancer cells to senolysis.

01-11-2022

Nature communications

A doxycycline- and light-inducible Cre recombinase mouse model for optogenetic genome editing.

28-10-2022

PloS one

Indisulam synergizes with palbociclib to induce senescence through inhibition of CDK2 kinase activity.

07-09-2022

Life science alliance

Genetic and compound screens uncover factors modulating cancer cell response to indisulam.

01-09-2022

Nucleic acids research

Division of labor within the DNA damage tolerance system reveals non-epistatic and clinically actionable targets for precision cancer medicine.

22-07-2022

Nature communications

A loss-of-adhesion CRISPR-Cas9 screening platform to identify cell adhesion-regulatory proteins and signaling pathways.

19-04-2022

Cancers

Ribociclib Induces Broad Chemotherapy Resistance and EGFR Dependency in ESR1 Wildtype and Mutant Breast Cancer.

16-12-2021

Molecular cell

Loss of nuclear DNA ligase III reverts PARP inhibitor resistance in BRCA1/53BP1 double-deficient cells by exposing ssDNA gaps.

18-11-2021

Key Publication

Genome medicine

Targeting CDC7 potentiates ATR-CHK1 signaling inhibition through induction of DNA replication stress in liver cancer.

18-10-2021

Molecular cancer research : MCR

Identification of Autophagy-Related Genes as Targets for Senescence Induction Using a Customizable CRISPR-Based Suicide Switch Screen.

01-10-2021

Cell reports

The Cancer SENESCopedia: A delineation of cancer cell senescence.

27-07-2021

Nature communications

Glucocorticoid receptor triggers a reversible drug-tolerant dormancy state with acquired therapeutic vulnerabilities in lung cancer.

16-07-2021

Nature

EGFR activation limits the response of liver cancer to lenvatinib.

01-07-2021

Scientific reports

A kinome-centered CRISPR-Cas9 screen identifies activated BRAF to modulate enzalutamide resistance with potential therapeutic implications in BRAF-mutated prostate cancer.

01-07-2021

EBioMedicine

It takes two to tango, and the right music: Synergistic drug combinations with cell-cycle phase-dependent sensitivities.

01-07-2021

Molecular cell

Impact of chromatin context on Cas9-induced DNA double-strand break repair pathway balance.

20-05-2021

A genome-wide CRISPR screen in human prostate cancer cells reveals drivers of macrophage-mediated cell killing and positions AR as a tumor-intrinsic immunomodulator.

Molecular Glue and Phosphorylation-Dependent 14-3-3 Recruitment to p53 with an Engineered Interaction Cassette.

Inhibition of mitochondrial protein translation sensitizes tumor cells to death receptor 5 agonistic antibody.

DOT1L Shapes ncPRC1-Target Gene Repression to Maintain Germinal Center B Cell Identity of Diffuse Large B cell Lymphoma.

Inducible CRISPR-Cas9 screening platform to interrogate non-proliferative cellular states.

CRISPR knockout screens reveal JUN as the master mediator of resistance to MAPK inhibition in KRAS-mutant pancreatic cancer.

Cholesterol biosynthesis as a drug-induced vulnerability in diffuse large B cell lymphoma insensitive to EZH2 inhibition.

Exploiting nanopore sequencing advances for tRNA sequencing of human cancer models.

CRISPR screens identify the ATPase VCP as a druggable therapeutic vulnerability in cholangiocarcinoma.

Epigenetic profiling identifies markers of endocrine resistance and therapeutic options for metastatic castration-resistant prostate cancer.

A functionally validated TCR-pMHC database for TCR specificity model development.

Molecular dependencies and genomic consequences of a global DNA damage tolerance defect.

An antibiotic that mediates immune destruction of senescent cancer cells.

P-stalk ribosomes act as master regulators of cytokine-mediated processes.

ADARp150 counteracts whole genome duplication.

Chromatin context-dependent effects of epigenetic drugs on CRISPR-Cas9 editing.

Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy.

Widespread chromatin context-dependencies of DNA double-strand break repair proteins.

Targeting of vulnerabilities of drug-tolerant persisters identified through functional genetics delays tumor relapse.

PARG-deficient tumor cells have an increased dependence on EXO1/FEN1-mediated DNA repair.

Luminal breast cancer identity is determined by loss of glucocorticoid receptor activity.

Locus-specific proteome decoding reveals Fpt1 as a chromatin-associated negative regulator of RNA polymerase III assembly.

PAXIP1 and STAG2 converge to maintain 3D genome architecture and facilitate promoter/enhancer contacts to enable stress hormone-dependent transcription.

Rational combination of SHP2 and mTOR inhibition for the treatment of hepatocellular carcinoma.

Multi-omics analysis reveals distinct non-reversion mechanisms of PARPi resistance in BRCA1- versus BRCA2-deficient mammary tumors.

Systematic screening identifies ABCG2 as critical factor underlying synergy of kinase inhibitors with transcriptional CDK inhibitors.

Inhibitor of Apoptosis Proteins Antagonist Induces T-cell Proliferation after Cross-Presentation by Dendritic Cells.

Subtype-specific kinase dependency regulates growth and metastasis of poor-prognosis mesenchymal colorectal cancer.

Inhibition of casein kinase 2 sensitizes mantle cell lymphoma to venetoclax through MCL-1 downregulation.

Genetic screens reveal new targetable vulnerabilities in BAP1-deficient mesothelioma.

Mammalian life depends on two distinct pathways of DNA damage tolerance.

Sustained activation of EGFR-ERK1/2 signaling limits the response to tigecycline-induced mitochondrial respiratory deficiency in liver cancer.

NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition.

An Unbiased CRISPR-Cas9 Screening Method for the Identification of Positive and Negative Regulatory Proteins of Cell Adhesion.

cFLIP suppression and DR5 activation sensitize senescent cancer cells to senolysis.

A doxycycline- and light-inducible Cre recombinase mouse model for optogenetic genome editing.

Indisulam synergizes with palbociclib to induce senescence through inhibition of CDK2 kinase activity.

Genetic and compound screens uncover factors modulating cancer cell response to indisulam.

Division of labor within the DNA damage tolerance system reveals non-epistatic and clinically actionable targets for precision cancer medicine.

A loss-of-adhesion CRISPR-Cas9 screening platform to identify cell adhesion-regulatory proteins and signaling pathways.

Ribociclib Induces Broad Chemotherapy Resistance and EGFR Dependency in ESR1 Wildtype and Mutant Breast Cancer.

Loss of nuclear DNA ligase III reverts PARP inhibitor resistance in BRCA1/53BP1 double-deficient cells by exposing ssDNA gaps.

Targeting CDC7 potentiates ATR-CHK1 signaling inhibition through induction of DNA replication stress in liver cancer.

Identification of Autophagy-Related Genes as Targets for Senescence Induction Using a Customizable CRISPR-Based Suicide Switch Screen.

The Cancer SENESCopedia: A delineation of cancer cell senescence.

Glucocorticoid receptor triggers a reversible drug-tolerant dormancy state with acquired therapeutic vulnerabilities in lung cancer.

EGFR activation limits the response of liver cancer to lenvatinib.

A kinome-centered CRISPR-Cas9 screen identifies activated BRAF to modulate enzalutamide resistance with potential therapeutic implications in BRAF-mutated prostate cancer.

It takes two to tango, and the right music: Synergistic drug combinations with cell-cycle phase-dependent sensitivities.

Impact of chromatin context on Cas9-induced DNA double-strand break repair pathway balance.

This site uses cookies